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Glioblastoma is the most aggressive brain cancer with the poor survival rate. A microRNA,
miR-451, and its downstream molecules, CAB39/LKB1/STRAD/AMPK, are known to play
a critical role in regulating a biochemical balance between rapid proliferation and invasion
in the presence of metabolic stress in microenvironment. We develop a novel multi-scale
mathematical model where cell migration and proliferation are controlled through a core
intracellular control system (miR-451-AMPK complex) in response to glucose availability
and physical constraints in the microenvironment.Tumor cells are modeled individually and
proliferation and migration of those cells are regulated by the intracellular dynamics and
reaction-diffusion equations of concentrations of glucose, chemoattractant, extracellular
matrix, and MMPs. The model predicts that invasion patterns and rapid growth of tumor
cells after conventional surgery depend on biophysical properties of cells, dynamics of
the core control system, and microenvironment as well as glucose injection methods. We
developed a new type of therapeutic approach: effective injection of chemoattractant to
bring invasive cells back to the surgical site after initial surgery, followed by glucose injection
at the same location.The model suggests that a good combination of chemoattractant and
glucose injection at appropriate time frames may lead to an effective therapeutic strategy
of eradicating tumor cells.
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1. INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and aggres-
sive form of primary brain tumor with the median survival time
of approximately 1 year from the time of diagnosis (Demuth and
Berens, 2004; Stylli et al., 2005; Jacobs et al., 2011). GBMs are
characterized by rapid proliferation and aggressive invasion into
surrounding normal brain tissue, which leads to inevitable recur-
rence after surgical resection of the primary tumor (Chintala et al.,
1999). Surgery is the primary treatment method, generally fol-
lowed by inefficient radiotherapy and chemotherapy. Innovative
therapeutic approaches of targeting these invasive cells are needed
in order to improve clinical outcome (Davis and McCarthy, 2001).
Glioblastoma cells are encountered with many challenges such as
hypoxia (lack of oxygen), acidity, and limited nutrient availabil-
ity as tumor growth is proceeded. To keep up with rapid growth,
tumor cells need to adapt to these biochemical changes in the harsh
microenvironment (Godlewski et al., 2010a). In order to over-
come these challenges and sustain their rapid growth, cancerous
cells change their typical metabolism (oxidative phosphorylation
and anaerobic glycolysis) to inefficient metabolic machinery [high
levels of glucose uptake and lactate production; Warburg Effect
(Warburg, 1956; Kim and Dang, 2006)].
The Krebs, or tricarboxylic acid (TCA) cycle is a main step for
generating an energy source, ATP, in non-hypoxic normal cells.
While this effective way of metabolism is used by differentiated
cells, tumor cells favor a seemingly less effective way of metabo-
lism, aerobic glycolysis (Heiden et al., 2009) due to production of
lactic acid, and consumption of large amounts of glucose (Kim
and Dang, 2006). Adapting this aerobic glycolysis (Gatenby and
Gillies, 2004), cancer cells appear to have an advantage of not
having to rely on oxygen for energy source in hypoxic (hostile)
microenvironment (Gatenby and Gillies, 2004; Kim and Dang,
2006). Better understanding of basic mechanism of glycolysis and
intracellular dynamics may provide better clinical outcomes. For
example, inhibition of glycolysis may prevent drug resistance (Xu
et al., 2005). Cancer cells also adapt angiogenesis and migra-
tion as a way of ensuring an adequate glucose supply (Godlewski
et al., 2010a). However, appropriate intracellular responses to glu-
cose withdrawal are a crucial component of adaptation in order
to survive periods of metabolic stress and maintain viability as
a tumor grows (Jones and Thompson, 2009). The 5′-adenosine
monophosphate activated protein kinase (AMPK) pathway is the
major cellular sensor of energy availability (Hardie, 2007) and is
activated in the presence of metabolic stress as a way of promoting
glucose uptake and energy conservation (Hardie, 2007). Dysreg-
ulation of miRNAs, 22 nucleotide single-stranded non-coding
RNAs (Bartel, 2009), has been associated with oncogenic activi-
ties and tumor suppressor (Esquela-Kerscher and Slack, 2006) in
many cancer types, including glioblastoma where alterations in
miRNA expression induces tumorigenesis (Godlewski et al., 2008;
Lawler and Chiocca, 2009). For example, miR-21 promote glioma
invasion by down-regulation of inhibitors of matrix metallopro-
tease (MMP) (Gabriely et al., 2008). In a recent paper, Godlewski
et al. (2010a) found that a particular microRNA, miR-451, deter-
mines glioma cell motility and proliferation by regulating its
counterpart, AMPK signaling component (CAB39/LKB1/AMPK),
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in response to various glucose levels. While normal glucose led to
up-regulation of miR-451 expression and rapid cell proliferation,
deprived glucose induced down-regulation of miR-451 and ele-
vated cell migration. Godlewski et al. (2010a) also found mutual
antagonism between miR-451 activity and AMPK complex lev-
els, which was modeled using a mathematical model in Kim et al.
(2011a). See Figure 1.
Invasion of glioma cells leads to treatment failure due to poor
screening of invasive individual cells by the standard clinical device
and difficulty in complete elimination of the migratory cells in typ-
ical brain surgery, causing tumor recurrence (Chintala et al., 1999).
Many factors may contribute to glioma cell motility in the brain
tissue. Extra cellular matrix (ECM) may stimulate glioma invasion
in a process known as haptotaxis. Haptotactic process is suggested
to be activated by pre-existing brain components and remodeling
of the ECM via proteolysis (Chintala et al., 1999; Jaalinoja et al.,
2000; Choe et al., 2002). Glioma cell’s motility is also influenced
by various chemoattractants, which include ligands of scatter fac-
tor/hepatocyte growth factor (SF/HGF) (Lamszus et al., 1998),
the EGF family (Lund-Johansen et al., 1990), the TGF-β family
(Platten et al., 2001), SDF-1 (Zhou et al., 2002), and certain lipids
(Young and Brocklyn, 2007). We note that other authors studied
the action of HGF or scatter factor on cell migration (Tamagnone
and Comoglio, 1997; Luca et al., 1999; Stella and Comoglio, 1999;
Trusolino and Comoglio, 2002; Scianna et al., 2009). Beside these
factors, other cell types such as microglia can also provide indi-
rect stimulation of cell migration by secreting matrix components
and chemoattractants (Watters et al., 2005). Glioma cell migra-
tion may be regulated by specific substrates and structures in the
brain as well. For instance, glioma cells are also known to follow
preferred dispersion paths such as white matter tracts or the basal
lamina of blood vessels. Invasion patterns of glioma cells in three-
dimensional tumor spheroids were studied in Kim et al. (2009)
FIGURE 1 | Biological observation for regulation of miR-451-AMPK
complex (Godlewski et al., 2010a).
where the migration patterns exhibit a gradual shift from branch-
ing to dispersion and depend on three key parameters (cell–cell
adhesion strength, haptotactic parameter, and chemotactic sensi-
tivity). There are several publications based on a diffusion model
(Swanson et al., 2003; Harpold et al., 2007).
Other authors investigated the transition between migration
and proliferation using kinetic or diffusion models (Chauviere
et al., 2010; Hatzikirou et al., 2010; Pham et al., 2012). A gen-
eral review on hybrid models of tumor growth can be found in
Rejniak and Anderson (2011). In the present paper, the detailed
dynamics of a core control system (miR-451-AMPK) at each cell
site is embedded in a hybrid model and is linked to extracellu-
lar glucose molecules which diffuse to brain tissue. In the hybrid
model, tumor cells either migrate or proliferate in response to
biochemical signals such as glucose and chemoattractants. Migra-
tory cells are attracted to chemotactic source and secrete MMPs
to degrade extracellular matrix (ECM). We show how the spatial
migrating patterns of glioma cells can be controlled by the core
system in the absence and presence of chemotactic source after
initial surgery and explore how injection of glucose and chemoat-
tractants could be manipulated for better therapeutic options.
More importantly, we use the current model to test hypotheses
on chemotaxis-glucose-driven therapy, i.e., eradicating “invisible”
invasive cells after surgery. We propose that injection of chemoat-
tractants after surgery followed by glucose injection at the tumor
site would bring migratory glioma cells back to the surgical site
and make them detectable by MRI, and the follow-up surgery may
improve clinical outcomes by eradicating the remaining growing
tumor cells.
In Section 2 we introduce a multi-scale mathematical model. In
Section 3, we present the results from the hybrid model. Discussion
and future work are provided in Section 4. Parameter estimation
and non-dimensionalization of the model are given in Appendix.
2. MATERIALS AND METHODS
In this section, we introduce a multi-scale mathematical model of
regulation of cell proliferation and migration in glioblastoma. We
consider a brain tissue,= [0, L]2, with glioblastoma tumor ini-
tially occupying a sphere0c = {x : |x | < R0,R0 < L}, where R0 is
the initial radius of the tumor spheroid. A schematic of the hybrid
model is shown in Figure 2. We first introduce the cell-mechanics
part of the model.
2.1. THE CELL-MECHANICS
The mechanical behavior of individual cells is based on the mod-
els developed by Dallon and Othmer (2004) and Kim et al. (2007,
2011b). The forces on a cell in the model include (i) the dynamic
drag forces from adhesive bonds with neighboring cells, (ii) the
active forces Ti exerted on the substrate or neighboring cells and
the reaction force (Mj,i), (iii) static friction force Sj,i for rigid
attachment between cells or between a cell and the substrate. (See
DO for a more detailed discussion of all forces involved.) The total
force on the ith cell is then given by
Fi =
∑
j∈N ai
Mj ,i +
∑
j∈N ai
Ti +
∑
j∈N di
µij(vj − vi)+
∑
j∈N si
Sj ,i (1)
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FIGURE 2 | (A) A schematic of the hybrid model for therapeutic
approaches. (Top) Simplified model of the core control system (miR-451
and AMPK complex) in response to various glucose levels at a tumor cell
site. The core system determines the cell fate, either proliferation or
migration. Chemoattractants in the brain tissue determine the migration
direction of the cell. (Bottom, Left) Model domain: some migratory
cancer cells (blue) near the tumor core site are activated to become a
proliferative one (green) via miR-451-AMPK regulation in response to
glucose injection levels (red thunder) at the center of the tumor site.
(Bottom, right) changes in the length of the a-axis of a cell (the ellipsoid)
under a given force (fa; arrow) consist of the passive change in the first
component (a Maxwell element in parallel with a non-linear spring) and
the change due to the growth (uga ). The growth component depends on
the levels of miR-451 and AMPK complex, and the force (fa). The
mechanical and growth elements are the same along all axes.
(B) miR-451 activity and levels of its target complex (CAB39/LKB1/AMPK)
were represented by “m” and “a,” respectively. (C) The migratory and
proliferative regions based on miR-451 activity and AMPK levels.
whereN ai denotes the neighbors of i, including the substrate, upon
which it can exert traction,N di is the set of “cells” (which includes
substrate and extracellular matrix) that interact with i via a fric-
tional force, and N si denotes the set of cells that statically bind
to cell i. These force balance equations allow us to calculate all
forces involved and track down locations of all cells in addition to
biophysical response of the cells.
There are two different kinds of cells involved-proliferative one
and motile one. The basic mechanical scheme of cell proliferation
is modeled as in Kim et al. (2007) and the basic algorithm for
motile cells is introduced as in Dallon and Othmer (2004). The
cells are treated as oriented ellipsoids and cytoplasm is con-
sidered as an incompressible, viscoelastic solid. When growth
is off, their volume is constant under all deformations. How-
ever, growth component (uag ) is included in series the active
response and the passive forces. (See Figure 2A.) We use the
multiplicative form of the growth rate function for the i-th axis
given by
(u
g
i )
′ = f (σ ) P (M ,A)
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where σ is the force acting on the cell and P is a function of the
miR-451 activity (M ) and AMPK levels (A). The growth func-
tion f (σ ) is defined so that cells can grow under sufficiently small
tensile and compressive forces (Kim et al., 2007, 2011b). The rela-
tionship between growth and stresses are complex and further
detailed modeling work is needed. Cell proliferation may depend
on up- or down-regulation of intracellular players that control the
cell cycle. In the present work, we assume that the core system
determines cell proliferation, i.e., a cell proliferates when miR-451
(AMPK) is up-regulated (down-regulated) at the cell site. Then,
the function P(M, A) is defined as
P (M ,A) =
{
1 if M > thM ,A < thA
0 otherwise
(2)
where thM, thA are threshold values of the miR-451 and AMPK
levels that will be introduced in Section 2.3. The active force Ti of
cell i is given by
Ti = φ (Mi) ∇C√
KC + |∇C |2
(3)
where C is the concentration of a chemoattractant. Here, the
indicator function φ(M ) is given by
φ (M ) =

rnF0 if M < thM ,A > thA , cell without
physical constraints,
0 otherwise,
(4)
where F0 is the basal magnitude of the active force (0≤ |Ti |≤ F0)
and rn is a random number in [0.8, 1.2]. Therefore, the active
force is completely turned off for proliferative cells (Mi> thM,
A< thA), cells under physical constraints (a cell completely sur-
rounded by neighboring cells), or in the absence of chemotactic
signal (∇C = 0).
2.2. REACTION-DIFFUSION
We let G(x, t ), C(x, t ), ρ(x, t ), P(x, t ) be the concentrations
of glucose, a chemoattractant of glioma cells, ECM, and MMPs,
respectively, at space x and time t. Governing equations of all
variables are given by
∂G
∂t
= DG1G︸ ︷︷ ︸
Diffusion
+
NG∑
j=1
λGinI[tGj ,tGj +τGd ]×︸ ︷︷ ︸
Injection
+ λbη1(x ,G)︸ ︷︷ ︸
Input
− λcη2(x ,G)︸ ︷︷ ︸
Consumption
− µGG︸︷︷︸
Removal
in, (5)
∂C
∂t
= DC1C︸ ︷︷ ︸
Diffusion
+
NC∑
j=1
λCinI[tCj ,tCj +τCd ]×︸ ︷︷ ︸
Injection
−µCC︸︷︷︸
Decay
in, (6)
∂ρ
∂t
= − λ1Pρ︸ ︷︷ ︸
Degradation
+ λ2ρ(1− ρ
ρ∗
)︸ ︷︷ ︸
Release/reconstruction
in, (7)
∂P
∂t
= DP1P︸ ︷︷ ︸
Diffusion
+ λ3η3 (x , P)︸ ︷︷ ︸
Production by cells
−µPP︸︷︷︸
Decay
in, (8)
where DG, DC, DP are the diffusion coefficients of glucose,
chemoattractant, and MMPs, respectively, λGin (λ
G
in) is the glu-
cose (chemoattractant) injection rate on a subdomain  over
time intervals [tGj , t
G
j + τGd ], j = 1, . . .,NG ([tCj , tCj + τCd ], j = 1,
. . ., NC) with a period τG (τC) and duration τGd (τ
C
d ) after the
initial surgery at t = tS (tG1 > tS), λb is the glucose flux from
a blood flow, λc is the consumption rate of glucose by tumor
cells, λ1 is the degradation rate of ECM by MMPs, λ2 is the
release/reconstruction rate of ECM, λ3 is the secretion rate of
MMPs by tumor cells,µG is the glucose removal rate from the sys-
tem via blood flow and glucose consumption in the surrounding
tissue (Chiro et al., 1982; Rozental et al., 1991; Goldman et al., 1996;
Aronen et al., 2000; Valle-Casuso et al., 2012), µC, µP are decay
rates of chemoattractant and MMPs, respectively. Here, indicator
functions (η1, η2, η3) are given by
η1 (x ,G) =
{
1 blood vessel
0 otherwise
, η2 (x ,G) =
{
1 tumor
0 otherwise
,
η3 (x , P) =
{
1 invasive cells
0 otherwise.
We also assume no flux (Neumann) boundary conditions
∂G
∂ν
= 0, ∂C
∂ν
= 0, ∂P
∂ν
= 0, on ∂. The reaction-diffusion equa-
tions (5–8) are solved on the regular grid using the alternating-
direction implicit (ADI) method and the non-linear solver
nksol for algebraic systems. A typical spatial grid size used is
hx= hy= 0.01 on a square domain [0, 1]× [0, 1]. An adaptive
time stepping method is used. Table 1 lists parameter values and
references values for the equations (5)-(8).
2.3. MATHEMATICAL MODELING OF miR-451-AMPK CONTROL
The core control model of miR-451 activity and AMPK levels
introduced in Kim et al. (2011a) was integrated into the hybrid
model. Based on biological observations, we write the phenome-
nological equations for the rate change of those key molecules (m,
a) as follows:
dm
dt
= λg g + 313
2
2
322 +35a2
− µ1m, (9)
da
dt
= s + 333
2
4
324 +36m2
− µ2a, (10)
where g is the signaling pathways from glucose to miR-451, s is
the signaling pathways to AMPK complex, 31, 33 are the auto-
catalytic enhancement parameters for miR-451, AMPK complex,
respectively, 32, 34 are the Hill-type inhibition saturation para-
meters from the counter part of miR-451 and AMPK complex,
respectively,35 is the inhibition strength of miR-451 by the AMPK
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Table 1 | Values of reference variables and parameters used in the hybrid model.
Var Description Value Refs.
DIFFUSION COEFFICIENTS
DG Glucose 6.7×10−7cm2/s Jain (1987)
DC Chemoattractant (EGF) 1.66×10−6 cm2/s Thorne et al. (2004)
DP MMPs 8.0×10−9 cm2/s Saffarian et al. (2004)
PRODUCTION/DECAY/CONSUMPTION RATES
λ2 ECM reconstruction/remodeling rate 5.6×10−3 s−1 TW
λ3 MMP production rate 5.8
λc Glucose consumption rate by tumor 0.8 pg/cell/min TW
µG Removal rate of glucose in brain tissue 0.0034 min−1 TW
µC Decay rate of chemoattractant (EGF) 8.02×10−6 s−1 Kudlow et al. (1986)
λ1 ECM degradation rate by MMPs 3.0×104 cm3 g−1 s−1 TW
µP Decay rate of MMPs 5.0×10−5 s−1 TW
REFERENCE VALUES
T Time 1 h
L Length 2.0 mm
G* Glucose concentration 4.5×10−3 g/cm3 Deisboeck et al. (2001), Sander and Deisboeck (2002), Godlewski et al. (2010a)
C* Chemoattractant (EGF) concentration 1.0×10−8 g/cm3 Boccardo et al. (2003), Sadlonova et al. (2005)
ρ* ECM concentration 1.0×10−3 g/cm3 Kaufman et al. (2005), Stein et al. (2007)
P* MMP concentration 1.0×10−7 g/cm3 Annabi et al. (2005)
complex, 36 is the inhibition strength of the AMPK complex by
miR-451,µ1,µ2 are microRNA/protein degradation rates of miR-
451 and AMPK complex, respectively. Table A1 in Appendix sum-
marizes the dimensionless parameters. By taking the thresholds
thM (=2.0) of miR-451 levels and thA (=2.0) of AMPK complex,
we shall define the migratory region Mm by Mm= {(M, A)∈R2:
M < thM, A> thA} and the proliferative region Mp by Mp= {(M,
A)∈R2: M > thM, A< thA}. See Figure 2C for a diagram for
proliferative and migratory regions.
3. RESULTS
In this Section, we present analysis of the hybrid model and pre-
dictions for therapeutic strategies for eliminating invasive glioma
cells.
3.1. DYNAMICS OF THE MODEL
In order to validate the mathematical model, we first investigated
invasion patterns of glioma cells embedded in high and low glucose
levels in the absence of blood supply of glucose (λb= 0), glucose
injection (λGin = 0) and chemoattractants, and by assuming cells
on the surface of the spheroid are migrating toward the glucose
gradient (∇G) [i.e., by replacing ∇C√
KC+|∇C | with
∇G√
KG+|∇G| in the
active force form in the equation (3)]. Figures 3A–C show spatial
profiles of tumor spheroids in response to high (G0= 1.0), inter-
mediate (G0= 0.5), and low (G0= 0.1) glucose levels. Figure 3D
shows relative miR-451 levels in response to high (Glucose+) and
low (Glucose−) levels in simulations and experiments (U251 and
LN229 cell lines) (Godlewski et al., 2010a). General patterns
of tumor spheroids in response to high (Figure 3A) and low
(Figure 3C) glucose levels in simulations are in good agree-
ment with experimental observations in Godlewski et al. (2010a)
where high (4.5 g/l) and low (0.3 g/l) levels of glucose induced
over- and under-expression of miR-451 (see Figure 3D), leading
to proliferating (as in Figure 3A) and dispersed invasive (as in
Figure 3C) patterns of tumor cells, respectively.
We investigate invasion dynamics of a growing tumor in
response to glucose levels in the presence of blood supply.
Figures 4A–C show spatial patterns of a growing/invading tumor
in response to glucose supply (G0= 10) at time t = 0, 20, 30 h.
Initial high glucose level is decreased due to glucose consump-
tion by tumor cells at the center of the domain and nearby
tissue (Figures 4D–F). The miR-451 activity at cell sites is
decreased and AMPK levels creep up due to decreased glucose
levels (Figures 4M,N). Cells on the surface of the tumor mass
immediately respond to intracellular biochemical signals (miR-
451 and AMPK levels) and begin to migrate when miR-451 level
drops below the threshold (M < thM= 2.0) and AMPK level is
up-regulated (A> thA= 2.0) due to decreased glucose level at
the cell site (cf. Figure 2C). However, cells at the center of the
tumor mass are surrounded by neighboring cells and stay inside
the tumor due to physical constraints despite biochemical migra-
tion signals (M < thM, A> thA). Figure 4N shows time courses
of miR-451 activities and AMPK levels in response to glucose
levels in Figure 4M at two cell sites [cell id= 220 with initial
location (108.2, 99.5); cell id= 160 with initial location (100.5,
99.8)]. The miR-451 levels for both cells drop below the thresh-
old (thM) and AMPK levels are above the threshold (thA) around
t = 16 h already, generating “migratory” signal. However, the cell
(marked in “gray”; cell id= 220) in Figure 4A still stays in the
tumor mass at t = 20 h (Figure 4B) and begins to shed off at later
time (t = 26 h; arrow in Figure 4N) when free space is available.
Another cell (cell id= 160) at the center of domain remains at the
center of the tumor due to physical constraints until final time
[t = 40 h; final location (100.3, 99.7)]. When glioma cells on the
surface of the tumor mass migrate into surrounding brain tissue,
proteinases (MMPs) are secreted in the invading front and ECM is
degraded due to high levels of MMPs (proteolysis). See localized
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FIGURE 3 | (A–C) Profiles of tumor spheroid in response to high (G=1.0),
intermediate (G=0.5), and low (G=0.1) glucose levels at t =30 h. Domain
size= [50µm, 150µm]× [50µm, 150µm]= [0.25, 0.75]2 in the
dimensionless domain [0, 1]2). (D) Comparison between simulation results
and experimental data. In response to high (Glucose+, blue) and low
(Glucose−, gray) glucose levels, miR-451 expression levels are quantified.
Simulation results are in good agreement with experimental results on U251
and LN229 cell line in Godlewski et al. (2010a). *λb = 0, λGin = 0. It was
assumed that tumor cells respond to the glucose gradient for migration
in vitro as in Godlewski et al. (2010a).
MMPs at cell sites and degraded ECM profiles in Figures 4G–L,
respectively.
Figures 5A–D show cyclic tumor growth patterns at t = 0, 20,
38, 46 h in response to periodic glucose injection. When high doses
(G= 10.0) of glucose are introduced into the system at t = 0, 26 h,
fluctuating glucose values (Figure 5E) at a cell site (cell id= 220;
arrowhead in Figures 5A–D) lead to a cycle of up-regulation and
down-regulation of miR-451 (Figure 5F). Cells outside the tumor
core respond to this stimulus by either proliferating or migrating.
See Figures 5A–D. Cell phenotype changes between proliferative
and migratory cells are more clear in Figure 5G. Initial prolifer-
ative cells due to high glucose levels change their phenotype to
become migratory cells whenever glucose level lowered to induce
migratory phase [M > thM, A< thA;∼t = 16 h (black arrow) and
t = 42 h (red arrow)]. These migratory cells change their phe-
notypes to proliferative cells (∼t = 26 h; black arrowhead) when
the high glucose level from glucose injection induces proliferative
phase (M > thM, A< thA).
3.2. SENSITIVITY OF THE MODEL TO INHIBITION PARAMETERS (α, β)
IN THE CORE SYSTEM
From now on, the activation time for invasion is defined to be time
when a cell in proliferative phase (M > thM, A< thA) changes
its phenotype to a migratory cell (M < thM, A> thA) due to a
microenvironmental change (glucose fluctuation) and begins to
migrate away from the main tumor aggregate for the first time
among all other cells. In Figure 6A we show steady state values
of miR-451 (Ms) in response to different glucose levels for vari-
ous inhibition strength (β) of AMPK complex by miR-451. See
Appendix A.2 for definition and role of β (and α below) in the
core system. As β is decreased the bifurcation curve shifts to the
right (higher glucose levels). In the control case (β = 1.0), a rela-
tively low glucose level (G= 0.4) is required for activation of cell
invasion. When this inhibition strength is weakened (β small),
a cell may begin to migrate for larger glucose levels. Figure 6B
shows activation time for invasion as a function of inhibition
strength of AMPK complex production (β). As β is decreased
from control base parameter (β = 1.0), the rate of AMPK com-
plex formation is increased and miR-451 level is decreased at
earlier time, leading to early activation time for invasion. This
might have biological implications. For example, one could totally
use or partially block inhibition pathways from miR-451 to AMPK
(decrease in β) in order to boost invasion activation under certain
circumstances.
Figures 7A,B show effect of inhibition strength (α) of miR-451
production by AMPK complex on tumor population and activa-
tion time for cell invasion. As the inhibition strengthα is increased,
miR-451 levels are decreased at earlier time (Figure 7B) and more
cells on the surface of the tumor mass migrate from the biochem-
ical signal. See Figure 7A. This would have several implications.
For example, cell migration or dispersion might be prevented by
any drug that blocks inhibitory activity of AMPK complex to miR-
451. This may generate faster growth of tumor mass since most of
cells would be in proliferative phase. Therefore, this could be used
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FIGURE 4 | (A–C) Tumor invasion pattern at time t =0, 20, 30 h in
response to glucose levels (G0 =10). Domain size= [0.25, 0.75]⊂ [0, 1]2.
(D–F) Profiles of glucose concentration on the domain [0, 1]× [0, 1].
Glucose flux from a blood vessel induces a peak value at the upper right
corner. (G–I) Profiles of ECM on the subdomain [0.25, 0.75]× [0.25,
0.75]⊂ [0, 1]2. ECM were degraded in the invasive region. (J–L) Profiles of
MMPs on the subdomain [0.25, 0.75]× [0.25, 0.75]⊂ [0, 1]2. MMPs are
localized in tumor region. (M) Glucose levels at two cell sites (cell id=220,
160). (N) Concentrations of intracellular variables, miR-451 and AMPK
complex, at the cell sites in (M).
as a temporary way of holding cell migration in order to not miss
out single migratory cells for surgery.
3.3. PREDICTIONS OF THE MODEL FOR A POSSIBLE THERAPEUTIC
APPROACH
In this section, we developed therapeutic strategies for eradi-
cating invisible migratory glioma cells in the brain after con-
ventional surgery where only visible parts of tumor mass are
removed. Here we assume that invasive cells in surrounding tis-
sue can sense and respond to the chemoattractant gradient (∇C).
Figures 8A–F show spatial profiles of the tumor cells at t = 0,
17, 25, 32, 39, 44 h, respectively. After first surgery (region inside
red doted circle in Figure 8A) at t = 0, a chemoattractant was
injected at the center of the resected area. See Figures 9D–F for
spatial profiles of chemoattractant at time t = 0, 16, 18 h. Invasive
cells begin to migrate back to the surgical site. After waiting 17 h
(tG1 = 17), a high dose of glucose was introduced into the system
at the center of surgical site and glucose molecule diffuses through
the domain (Figures 9A–C). High glucose levels trigger the intra-
cellular switch from the migratory phase to the proliferative mode
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FIGURE 5 | (A–D) Tumor growth patterns at t = 0, 20, 38, 46 h in response to
glucose injection. Two cycles of proliferation-migration pattern are observed
after initial (t =0 h) and second (t =26 h) injections of glucose (G=10).
Domain size= [0.2, 0.8]× [0.2, 0.8]⊂ [0, 1]2. (E) Glucose level at a cell site
[cell id=220; arrowhead in (A–D)]. (F) Time course of miR-451 activity and
AMPK concentration at the cell site in (E). Dotted black line in the
middle= threshold value of miR-451 (thM). (G)Time course of cell populations:
proliferative (blue square), migratory (red diamond), and total (black circle)
cells. Some of proliferative cells become migratory ones around t = 16 h (black
arrow) and t =42 h (red arrow) when miR-451 levels drop below threshold
due to lowered glucose levels. All migratory cells enter the proliferative phase
around t =26 (black arrowhead) in response to glucose injection.
FIGURE 6 | (A) Steady state values of miR-451 (Ms) as a function of
glucose level (G) for various inhibition strength of AMPK by miR-451 (β) in
core control system. (B) Effect of the inhibition rate (β) on activation time
for glioma cell invasion in the hybrid model. As β is decreased, activation
time for invasion is decreased. See Appendix A.2 for definition and role of
β in the core system.
for invasive cells near the injection site (Figure 9G). Figure 9G
shows time courses of miR-451 activity and AMPK level at two
cell sites (cell id= 36, 37). A cell (cell id= 36) close to the center
of the resection site is activated for proliferation at the earlier time
(∼t = 17). Green cells inside the blue dotted circle in Figure 8B
represent proliferative cells due to high glucose levels while red
cells outside the blue circle are still migratory cells in migratory
phase (M < thM, A> thA) from low glucose levels. While infiltra-
tive tumor cells after surgery may not be detected, regrown tumor
mass may be detected by conventional screening tools such as
MRI when tumor density is high enough. This may increase the
probability of eliminating invasive cells.
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FIGURE 7 | (A) Effect of miR-451 inhibition strength (α) on tumor
population. As α is increased, miR-451 production rate is decreased leading
to low miR-451 activity and activation of glioma cell migration. (B) Effect of
α on activation time for cell invasion. As α is increased, lowered miR-451
activity leads to early activation of cell invasion. See Appendix A.2 for
definition and role of α in the core system.
Figure 10 shows time courses of average cell speeds of migra-
tory (solid circle, red) and proliferative (blue square) cells in
Figure 8. From the beginning of the simulation, the average
cell speed of cells in migratory phase maintained the values in
the rage of 27–33µm/h until cell speeds begin to drop down
around ∼17 h due to cell aggregation at the center of domain.
Eventually all migratory cells become proliferative cells around
t = 19 h. Proliferative cells (blue square, transformed from migra-
tory cells around 9 h) show very low cell speeds due to absence
of active force since their movement is due to growth not cell
movement. Cell speeds have been reported to be in the range
of 39–45µm/h in 2D barrier-free culture condition and 15–
20µm/h in 3D glioblastoma cell culture in the absence/presence
of EGF-stimulation (Kim et al., 2008), 15–25µm/h in glioblas-
toma cells with/without α-actinin isoforms (Sen et al., 2009),
15–48µm/h for cells embedded in collagen I matrix (Kaufman
et al., 2005). So, the cell speed in our model is in good agreement
with experimental data.
To test our hypothesis in a more realistic situation, we tested
our hypothesis of attracting cancer cells back to the resection bed
in a more realistic setting in Figure 11. Here we assume that a cell
can sense the environment of the resection bed and stop moving
on the edge of the resection bed. In our simulation, generation of
active force of a migratory cell is turned off, i.e., active force Ti in
the equation (3) is set to be zero when the cell reaches periphery
of the resection bed. The simulation begins immediately after ini-
tial surgery of the large tumor mass at the center of the domain
again. Figures 11A–H show proliferation and migration patterns
of tumor cells at t = 0, 8, 16, 24, 32, 40, 48, 56 h in response to
initial injection of a chemoattractant (t = 0 h) followed by glucose
injection at t = 17 h. Figures 11I,J show time courses of miR-451
activity and AMPK level at a cell site (cell id= 22) and cell pop-
ulations [proliferative (blue circle), migratory (red dotted), and
total (green square) cells], respectively. Initially, there exist only
a phenotype of migratory cells but these cells begin to aggre-
gate on the periphery of the resection bed. However, these cells
switch their phenotype to proliferative ones via core control system
(Figure 11I) in response to glucose injection at t = 17 h. These
proliferative cells form a visible larger tumor mass which can be
ready for the second follow-up surgery. Most of these proliferative
cells enter the migratory phase (M < thM, A> thA) again around
t = 49 h due to lowered glucose levels.
3.4. THERAPEUTIC OPTIMIZATION
In Figures 12A–F, we investigate the effect of glucose injection
time on tumor growth patterns for chemoattractant-induced sec-
ond surgery under same conditions as in Figure 8. Figures 12A–D
illustrate spatial growth patterns of tumor cells at final time
(t = 44 h) when a high dose of glucose was injected at the cen-
ter of the surgical site at different initial injection time (tG1 =
10, 12, 15, 17 h). When glucose was injected at the earlier time
(tG1 = 10 h), more invasive cells enter the cell cycle (M > thM,
A< thA) for higher flux of glucose before they reach the surgi-
cal site. For the case of glucose injection at later time (tG1 = 17 h),
more cells are localized at the center of the surgical site. Figure 12E
shows tumor population at final time. Cells inside the bigger size of
tumor mass are subject to slower growth (see mechanical aspects of
the hybrid model). Initial glucose injection time decreases tumor
population since more tumor cells are activated for proliferation
and tumor cells grow faster without physical constraints. This
injection time also decreases resection area for second surgery due
to localized tumor cells at the original surgical site (Figure 12F).
Therefore, choosing appropriate injection time is important for
efficacy of tumor treatment. However, any further delay of second
surgery would lead to larger size of tumor mass and one may face
another possibility of tumor invasion.
Next, we investigate the effect of chemoattractant strength
on efficacy of therapeutic strategies suggested in this paper.
Figures 13A–F show migration-proliferation patterns of tumor
cells at t = 0, 17, 56 h in the presence of low (λCin = λC/10in ) and
high (control) levels of a chemoattractant and glucose injection at
t = 17 h after initial surgery at t = 0 h. When the chemoattractant
level is low, cells in the far away field do not effectively respond
to the chemotactic signals (red arrows in Figure 13B) and do
not move toward the resection bed easily, which induces further
tumor growth later at the undesirable location (black arrowheads
in Figure 13C). Figures 13G,H show populations of localized cells
(cells with d < 0.25) and cells outside the localized domain (cells
with d > 0.25), respectively. Here,d =
√
(xi − 0.5)2 + (yi − 0.5)2
is the distance from cell location (xi, yi) to the center (0.5, 0.5)
of the domain. One can see that the low chemoattractant level
leads to a moderate decrease in the population of localized cells
(Figure 13G) but induces a significant increase in the popula-
tion of cells in the far away field (Figure 13H) at t = 17, 56 h.
These missed cells reduce efficacy of second surgery. These results
effectively show that enough levels of chemoattractant need to be
provided for the more efficient therapy.
4. DISCUSSION
One major challenge for treating glioblastoma is that by the
time the disease is diagnosed cancer cells have already invaded
other parts of the brain, inhibiting complete elimination of can-
cer cells. Blocking this critical invasion process or finding a
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FIGURE 8 | Strategy of eradicating migratory cells after first surgery.
(A–F) Spatial profile of a surgically removed tumor at t =0, 17, 25, 32, 39,
44 h. Detectable tumor core was surgically removed at t =0 h (red dotted
circle) and a chemoattractant was injected at the center of the removed area
immediately after surgery (t =0 h). After waiting 17 h, glucose was injected at
the center of the removed area again in order to turn the migratory switch
(M < thM, A> thA) off and make these cells grow (M > thM, A< thA). This
growing mass of tumor may be visible for secondary surgery, leading to
eradication of invisible migratory cells. Domain size= [0.25, 0.75]× [0.25,
0.75]⊂ [0, 1]2.
FIGURE 9 | (A–C) Spatial profiles of glucose at t =0, 16, 18 h. Glucose was
injected at the center of the domain around t =17 h. Glucose flux from a
blood vessel induces a peak value at the upper right corner. (D–F) Spatial
profiles of chemoattractant at t =0, 16, 18 h. Chemotactic source was located
at the center of the domain. (G) Time course of the miR-451 activity and
AMPK level at two cell sites (cell id=36, 37). *Domain size in (A–F)= [0, 1]2.
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way of eradicating invasive tumor cells would lead to better
clinical outcomes. Godlewski et al. (2010a) recently identified
a key miRNA, miR-451, and its target, AMPK complex, that
FIGURE 10 | Cell speeds of proliferative (blue square) and migratory
(solid circle, red) cells in Figure 8.
regulates a critical switch between cell migration and prolifera-
tion. Reduced miR-451 activity has been associated with cancers
(Bandres et al., 2009) including glioma (Gal et al., 2008; Godlewski
et al., 2010a). In the harsh microenvironment, glioblastoma cells
shift their metabolic machinery toward a high level of glucose
uptake, Warburg effect (Warburg, 1956; Kim and Dang, 2006;
Heiden et al., 2009), and lowered glucose levels trigger active
cell migration toward the better microenvironment. Some up-
regulated miRNAs in brain tumors are believed to play a pro-
oncogenic role via supporting growth, proliferation, migration,
and survival of cancer cells while expression of other miRNA
having anti-tumor effects is suppressed in gliomas. These miR-
NAs harbor a therapeutic significance as therapeutic agents in
anti-cancer therapy (Lawler and Chiocca, 2009; Godlewski et al.,
2010b; Chistiakov and Chekhonin, 2012). Godlewski et al. (2010a)
illustrated glucose regulation of proliferation and migration of
glioma cells: (i) low glucose⇒ down-regulation of miR-451 and
up-regulation of the AMPK complex⇒ cell migration (ii) normal
(high) glucose⇒ up-regulation of miR-451 and down-regulation
of AMPK complex⇒ proliferation.
FIGURE 11 | (A–H) Tumor migration-proliferation patterns at t =0, 8, 16,
24, 32, 40, 48, 56 h in response to injection of a chemoattractant at t =0 h
and glucose at t =17 h after initial surgery at t =0 h. Migratory cells switch
to proliferative phenotype, forming a visible larger tumor mass, in
response to glucose for second follow-up surgery. Migratory cells stop on
the periphery of the resected area from the first surgery. It was assumed
that a cell can sense the environment of the resection bed and the active
force of a migratory cell is set to be zero when the cell reaches the
periphery of the resection bed. Domain size= [0.2, 0.8]× [0.2, 0.8]⊂ [0,
1]2. (I) Time course of miR-451 activity and AMPK level at a cell site (cell
id=22). Dotted black line in the middle= threshold value of miR-451
(thM =2.0). (J) Time course of cell populations: proliferative (blue circle),
migratory (red dotted), and total (green square) cells. All migratory cells
switch to proliferative ones around t =17 h when low miR-451 levels jump
to higher value [M > 5 in (I)] and the level stays above threshold
(thM = 2.0) due to glucose injection. Most of these proliferative cells enter
the migratory phase (M < thM, A> thA) again around t =49 h due to
lowered glucose levels. Parameters used: tG1 = 17 h, τGd = 24 h.
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FIGURE 12 | Optimal strategy for glucose injection for second
surgery after attracting invasive cells via chemotaxis. (A–D) Growth
patterns at final time (t = 33 h) for various glucose injection time
(tG1 = 10 (A), 12(B), 15 (C), 17 h(D)). Domain size= [0.2, 0.8]× [0.2,
0.8]⊂ [0, 1]2. (E) Tumor population for different tG1 . Tumor population is
decreased as tG1 is increased due to delay of growth signal.
(F) Resection area for second surgery for various tG1 . Resection area is
decreased as injection time is increased.
Conventional treatment options such as radiotherapy and
chemo therapy after surgical resection of tumor mass lead to poor
clinical outcome in many cases of glioblastoma due to invisible
migratory cancer cells in the brain tissue. In the present paper we
aimed at understanding a basic mechanism of proliferation and
migration of glioma cells in response to fluctuating glucose lev-
els and developing therapeutic strategies for eradicating invasive
glioma cells after initial conventional surgery. The present paper
develops a hybrid mathematical model of glioma cell migration
and proliferation. The hybrid model considers proliferation and
migration of individual tumor cells based on cell-mechanics, con-
centrations of glucose, chemoattractant, ECM, and MMPs in a
spatio-temporal domain, and regulation of key intracellular mol-
ecules, miR-451 and AMPK complex, at each cell site. Mechanical
stress and active forces acting on tumor cells were taken into
account in the model. The spatial distribution of both prolifer-
ative and migratory cells in response to high and low glucose
levels is in good agreement with experiments (Godlewski et al.,
2010a).
We first considered the important role that the core control sys-
tem (miR-451, AMPK) plays in regulation of the migratory phase
and proliferative phase when cells on the surface of tumor mass
begin to migrate away from the main core in the harsh microenvi-
ronment where glucose levels fluctuate. We analyzed the migratory
behavior of cells in response to variations in two key parame-
ters, inhibition strength of miR-451 (α) and inhibition strength
of AMPK complex (β), that play a critical role in characterizing
the invasion of glioma cells. Active migration of a cell depends
on chemical signals from the core miR-451-AMPK system and
their physical microenvironment in response to glucose injection.
Growing tumor cells in the presence of abundant glucose switch
their mechanism for cell migration when glucose is not available
and cells are not subject to physical constraints. When glucose was
introduced into the system in a periodic fashion, tumor repeat
migration-proliferation cycle, which may lead to faster growth
(Kim et al., 2011a).
For therapeutic strategies, the model suggested that (i) Intro-
duction of chemoattractant at the surgical site may bring these
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FIGURE 13 | Effect of chemoattractant strength (λCin) on efficacy of the
therapy. (A–F) Tumor migration-proliferation patterns for low (λ
C
in = λC/10in ) and
high (control) levels of a chemoattractant at t =0, 17, 56 h. A high dose of
glucose was injected at t =17 h after initial surgery at t =0 h. When the
chemoattractant level is low, cells in the far away field do not effectively
respond to the chemoattractant (red arrows in (B)), which induces further
growth later at the undesirable location (black arrowheads in (C)). Domain
size= [0.1, 0.9]× [0.1, 0.9]⊂ [0, 1]2. (G) Populations of localized cells (cells
with d <0.25) for low (10-fold smaller) and high levels of chemoattractant.
Here, d =
√
(xi − 0.5)2 + (yi − 0.5)2 is the distance from cell location (xi, yi) to
the center (0.5, 0.5) of the domain. (H) Same as in (G) but for cells outside the
localized domain (cells with d >0.25). Parameters used: tG1 = 17 h, τGd = 24 h.
invasive tumor cells back to the tumor site. (ii) Glucose injection
at the center of the surgical site would lead to up-regulation of
miR-451 and down-regulation of AMPK complex, which induces
cell proliferation. (iii) Follow-up surgery may eradicate the tumor
cells that managed to survive from the first surgery. Multiple
microsurgical resections for glioblastoma have been proven to be
effective and useful (Hong et al., 2012). However, we also found
that glucose injection at the wrong time may grow the tumor even
before tumor cells gather together and this may lead to undesirable
results, faster growth of dispersed tumor mass. Detecting appro-
priate time glucose injection and second surgery might also be a
challenge. Tumor cells can be cultured from biopsies up to 4 cm
away from the bulk tumor (Silbergeld and Chicoine, 1997). When
cancer cells migrate too far from the original site, it may be dif-
ficult to attract these cells. For example, we found that too low
chemoattractant may not be able to attract all migratory cells for
second surgery (Figure 12) and these missed cells would decrease
efficacy of the therapy. Therefore, in order to attract those invasive
cells in the far away field (>4 cm away) one might need strong
chemoattractants at the resection bed. However, this new strat-
egy in this paper may be a novel way of eliminating all cancer
cells when an appropriate combination of chemoattractants and
glucose is used.
The analysis and predictions of the hybrid model in this paper
may serve as a starting point for experimentation and more
detailed modeling. We indicate several aspects and directions for
further development of in vivo and/or in vitro multi-scale models:
(i) One might use a multi-phase approach to describe the inho-
mogeneity of the microenvironment (Byrne and Preziosi, 2004;
Preziosi and Tosin, 2009; Preziosi and Vitale, 2011). See a review
(Lowengrub et al., 2010) for further discussion. (ii) It has been
suggested that some glioma cells may migrate while they grow. We
could incorporate this aspect easily in this hybrid framework. Col-
lective cell migration is also considered as a key aspect of tumor
invasion (Friedl and Alexander, 2011). Creating a microtrack of
locally digested ECM followed by generating a larger excavated
macrotrack by proteolysis was suggested as a way of collective
cell migration (Wolf et al., 2007; Friedl and Alexander, 2011; Ilina
et al., 2011). In recent study, Sampetrean et al. (2011) also illus-
trated the importance of collective migration along fiber tracts
in glioma cell invasion, suggesting the need for anti-invasion
approach. (iii) The simplified network of miR-451 and AMPK
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complex can be extended to the more detailed network in order to
take into account cell cycle and other anti-cancer molecules. (iv)
Some important players such as immune cells and cytokines in
the microenvironment should be included in the model (Cheng
and Weiner, 2003; Rejniak and McCawley, 2010; Wiranowska and
Rojiani, 2011). (v) It was observed that isoforms of myosin II are
specifically required for an adaptation needed to squeeze through
the dense network of other cells (Beadle et al., 2008). Detailed
modeling work is necessary to take into account deformation of
cell body for cell motility. We hope to address these issues in
future work.
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A. APPENDIX
A.1. PARAMETER ESTIMATION AND NON-DIMENSIONALIZATION
A.1.1. Tumor module
The characteristic distance is the maximum domain size
(L= 2 mm) of growing glioblastoma within 48 h similar to the
size of the migratory region in the experiments by Godlewski et al.
(2010a) and we use T = 1 h to get dimensionless variables and
parameters:
t¯ = t
T
, x¯ = x
L
, G¯ = G
G∗
, C¯ = C
C∗
, ρ¯ = ρ
ρ∗
, P¯ = P
P∗
,
D¯G = T
L2
DG , D¯C = T
L2
DC ,
D¯P = T
L2
DP , λ¯
G
in =
TλGin
G∗
, λ¯b = Tλb
G∗
, λ¯c = Tλc
G∗
,
λ¯Cin =
TλCin
G∗
, λ¯1 = Tλ1P∗,
λ¯2 = Tλ2, ρ¯∗ = ρ∗
ρ∗
, λ¯3 = Tλ3, µ¯G = TµG ,
µ¯C = TµC , µ¯P = TµP ,
(A1)
We estimate some of parameters and reference values in
the following. (i) DG: diffusion coefficients of glucose (G)
were measured to be 6.7× 10−7 cm2/s in the brain (Jain,
1987) and 1.3× 10−6 cm2/s in collagen gel (Rong et al., 2006).
We take DG= 6.7× 10−7 cm2/s as in Jain (1987). (ii) DP: in
experiments of the movement of MMP-1in the collagen fib-
ril, Saffarian et al. (2004) estimated the diffusion coefficient
of MMPs as (8.0± 1.5)× 10−9 cm2/s for inactive mutant and
(8.0± 1.5)× 10−9 cm2/s for wild-type activated MMP-1, respec-
tively. For our simulation, we take DP= 8.0× 10−9 cm2/s. (iii)
DC: the diffusion coefficient of chemoattractant was taken
from one of EGF, DC= 1.66× 10−6 cm2/s from Thorne et al.
(2004). (iv) λc (glucose consumption rate): the measured level
α= 1.6 pg/cell/min for piecewise increasing linear consumption
termα(G)n was used in a glioma invasion study (Sander and Deis-
boeck, 2002) along with a threshold valueGth1 = 2.0×10−4 g/cm3,
taken from the work of Li (1982). We take λc= 0.8 pg/cell/min
and use a sphere with a radius r = 8–20µm for estimation of
cell volume. (v) G∗: Sander and Deisboeck (2002) used the char-
acteristic concentration of glucose 2× 10−4 g/cm3, and took the
value 6× 10−4 g/cm3 for glucose level far from the tumor (see
also Deisboeck et al., 2001). Kim et al. (2009) took 6× 10−4 g/cm3
as a reference value based on experimental observation. In
in vitro experimental study (Godlewski et al., 2010a), high
(4.5 g/l= 4.5× 10−3 g/cm3) and low (0.3 g/l= 3.0× 10−4 g/cm3)
levels of glucose induced the up- and down-regulated miR-451
expression. We take the high glucose level,G∗= 4.5× 10−3 g/cm3,
as a reference value. (vi) ρ∗: collagen is one of main ECM com-
ponents. ECM concentration was estimated to be 0.5–2.0 mg/ml
in an experimental study of growth patterns of glioma spheroids.
Stein et al. (2007) investigated growth patterns of glioma cell lines
in experiments where U87 wild-type and its mutant, U87DEGFR,
were implanted into collagen I of concentration of 2.6 mg/ml.
We take ρ∗= 1.0 mg/cm3 as our reference value of ECM. (vii)
P∗: in a breast cancer cell invasion study, MMP concentrations
were measured to be 1.6× 10−9 g/cm3 (Jia et al., 2004). On the
other hand, it was shown that PCK3145 can down-regulate MMP-
9 level in prostate cancer patients with up-regulated MMP-9 level
of>100µg/l (Annabi et al., 2005). We take the high levels of MMPs
(P∗= 100µg/l) as our reference value of MMPs.
Table 1 lists reference values and all parameter values above.
A.1.2. Core control system (miR-451, AMPK)
We use the following dimensionalization scheme to get the
dimensionless key control parameters (Kim et al., 2011a).
τ = µ1t ,M = m
m∗
,A = a
a∗
,G = g
m∗
, lg = 3g
µ1
,
S = s
µ2a∗
, l1 = 313
2
2
µ1m∗
, l2 = 32,
l3 = 333
2
4
µ2a∗
, l4 = 34,α = 35(a∗)2,
β = 36(m∗)2,  = µ1
µ2
,
(A2)
and the dimensionless form of core control system
dM
dτ
= lgG + l1
l22 + αA2
−M , (A3)

dA
dτ
= S + l3
l24 + βM 2
− A. (A4)
Table A1 | Parameters that are used in the intracellular miR-451-AMPK
system.
Description Value Refs.
lg Glucose signaling rate 1.0 Kim et al. (2011a)
l1 Autocatalytic production rate
of miR-451
4.0 Kim et al. (2011a)
l2 Hill-type coefficient 1.0 Kim et al. (2011a)
α Inhibition strength of miR-451
by AMPK complex
1.6 Kim et al. (2011a)
thM Threshold of AMPK for
proliferation/migration switch
2.0 Estimated
l3 Autocatalytic production rate
of AMPK
4.0 Kim et al. (2011a)
l4 Hill-type coefficient 1.0 Kim et al. (2011a)
β Inhibition strength of AMPK
complex by miR-451
1.0 Kim et al. (2011a)
S Signaling source of AMPK 0.2 Kim et al. (2011a)
∈ Scaling factor (slow
dynamics) of AMPK complex
0.02 Crute et al. (1998);
Aguda et al. (2008);
Gantier et al. (2011);
Kim et al. (2011a)
thA Threshold of AMPK for
proliferation/migration switch
2.0 Estimated
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